Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Harrington

Showing results (171-180 of 197) with videos related to

Pageof 20
Sort By:
Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
JAMA|March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialRobert Haddad, Jérôme Fayette, Maria Teixeira, et al.
British Journal of Cancer|May 26, 2018
Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams)Christian Grønhøj, David H Jensen, Christian Dehlendorff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> MutationsAlan L Ho, Irene Brana, Robert Haddad, et al.
Science Translational Medicine|June 16, 2012
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsRobert A Adair, Victoria Roulstone, Karen J Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Max Robinson, Andrew Hartley, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Lisa Licitra, Kevin Harrington, et al.
Pageof 20

Showing results (171-180 of 197) with videos related to

Sort By:
Pageof 20
Nature Communications|March 27, 2021
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapyTimothy Kottke, Jason Tonne, Laura Evgin, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
JAMA|March 13, 2025
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialRobert Haddad, Jérôme Fayette, Maria Teixeira, et al.
British Journal of Cancer|May 26, 2018
Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams)Christian Grønhøj, David H Jensen, Christian Dehlendorff, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> MutationsAlan L Ho, Irene Brana, Robert Haddad, et al.
Science Translational Medicine|June 16, 2012
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patientsRobert A Adair, Victoria Roulstone, Karen J Scott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2022
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651Robert I Haddad, Kevin Harrington, Makoto Tahara, et al.
Lancet (London, England)|November 20, 2018
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trialHisham Mehanna, Max Robinson, Andrew Hartley, et al.
JAMA Oncology|June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical TrialBarbara Burtness, Robert Haddad, José Dinis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2025
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab Plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaJérôme Fayette, Lisa Licitra, Kevin Harrington, et al.
Pageof 20